FABP1 and acute kidney injury: The Kaplan–Meier primary-endpoint free survival rates were 83.5% in patients without increased L-FABP or creatinine-defined AKI (n = 612), 75.7% in patients without creatinine-defined AKI who had increased L-FABP (n = 300), 77.3% in patients with creatinine-defined AKI who did not have increased L-FABP (n = 75), and 61.4% in patients with both increased L-FABP and creatinine-defined AKI (n = 132) (p < 0.001; Figure 2).